Elotuzumab: First Global Approval

Drugs
Anthony Markham

Abstract

Elotuzumab (Empliciti™) is a humanised IgG1 monoclonal antibody developed by Bristol-Myers Squibb (BMS) and AbbVie that has been approved as combination therapy with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in the US. Elotuzumab binds to the cell surface receptor signalling lymphocytic activation molecule F7 (SLAMF7), which is selectively expressed on myeloma cells and natural killer cells, leading to antibody-dependent cellular cytotoxicity and direct natural killer cell activation. In a phase III clinical trial, addition of elotuzumab to lenalidomide and dexamethasone therapy in patients with relapsed/refractory multiple myeloma was associated with a significant improvement in progression-free survival and overall response rate. This article summarizes the milestones in the development of elotuzumab leading to this first approval for relapsed/refractory multiple myeloma.

References

May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric D HsiMarna B Williams
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrzej J JakubowiakKenneth C Anderson
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators

❮ Previous
Next ❯

Citations

Apr 6, 2021·Bioactive Materials·Yujun ZengKui Luo
Jul 4, 2020·Anti-cancer Agents in Medicinal Chemistry·Navgeet KaurRakesh K Sindhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Related Papers

The New England Journal of Medicine
Sagar LonialELOQUENT-2 Investigators
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sagar LonialSundar Jagannath
© 2021 Meta ULC. All rights reserved